Cargando…

The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide

The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Qiu-Xu, Luo, Xiaofang, Lei, Zi-Ning, Wang, Jing-Quan, Wurpel, John, Qin, Zuodong, Yang, Dong-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409168/
https://www.ncbi.nlm.nih.gov/pubmed/32707710
http://dx.doi.org/10.3390/cancers12071963
_version_ 1783568003188654080
author Teng, Qiu-Xu
Luo, Xiaofang
Lei, Zi-Ning
Wang, Jing-Quan
Wurpel, John
Qin, Zuodong
Yang, Dong-Hua
author_facet Teng, Qiu-Xu
Luo, Xiaofang
Lei, Zi-Ning
Wang, Jing-Quan
Wurpel, John
Qin, Zuodong
Yang, Dong-Hua
author_sort Teng, Qiu-Xu
collection PubMed
description The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux pumps of anticancer drugs. Over the past decades, antimicrobial peptides have been investigated as a new generation of anticancer drugs and some of them were reported to have interactions with ABC transporters. In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Furthermore, XH-14C could stimulate the ATPase activity of ABCB1 and the molecular dynamic simulation revealed a stable binding pose of XH-14C-ABCB1 complex. There was no change on the expression level or the location of ABCB1 transporter with the treatment of XH-14C. Our results suggest that XH-14C in combination with conventional anticancer agents could be used as a novel strategy for cancer treatment.
format Online
Article
Text
id pubmed-7409168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74091682020-08-26 The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide Teng, Qiu-Xu Luo, Xiaofang Lei, Zi-Ning Wang, Jing-Quan Wurpel, John Qin, Zuodong Yang, Dong-Hua Cancers (Basel) Article The overexpression of ATP-binding cassette (ABC) transporters is a common cause of multidrug resistance (MDR) in cancers. The intracellular drug concentration of cancer cells can be decreased relative to their normal cell counterparts due to increased expression of ABC transporters acting as efflux pumps of anticancer drugs. Over the past decades, antimicrobial peptides have been investigated as a new generation of anticancer drugs and some of them were reported to have interactions with ABC transporters. In this article, we investigated several novel antimicrobial peptides to see if they could sensitize ABCB1-overexpressing cells to the anticancer drugs paclitaxel and doxorubicin, which are transported by ABCB1. It was found that peptide XH-14C increased the intracellular accumulation of ABCB1 substrate paclitaxel, which demonstrated that XH-14C could reverse ABCB1-mediated MDR. Furthermore, XH-14C could stimulate the ATPase activity of ABCB1 and the molecular dynamic simulation revealed a stable binding pose of XH-14C-ABCB1 complex. There was no change on the expression level or the location of ABCB1 transporter with the treatment of XH-14C. Our results suggest that XH-14C in combination with conventional anticancer agents could be used as a novel strategy for cancer treatment. MDPI 2020-07-19 /pmc/articles/PMC7409168/ /pubmed/32707710 http://dx.doi.org/10.3390/cancers12071963 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Teng, Qiu-Xu
Luo, Xiaofang
Lei, Zi-Ning
Wang, Jing-Quan
Wurpel, John
Qin, Zuodong
Yang, Dong-Hua
The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title_full The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title_fullStr The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title_full_unstemmed The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title_short The Multidrug Resistance-Reversing Activity of a Novel Antimicrobial Peptide
title_sort multidrug resistance-reversing activity of a novel antimicrobial peptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409168/
https://www.ncbi.nlm.nih.gov/pubmed/32707710
http://dx.doi.org/10.3390/cancers12071963
work_keys_str_mv AT tengqiuxu themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT luoxiaofang themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT leizining themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT wangjingquan themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT wurpeljohn themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT qinzuodong themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT yangdonghua themultidrugresistancereversingactivityofanovelantimicrobialpeptide
AT tengqiuxu multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT luoxiaofang multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT leizining multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT wangjingquan multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT wurpeljohn multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT qinzuodong multidrugresistancereversingactivityofanovelantimicrobialpeptide
AT yangdonghua multidrugresistancereversingactivityofanovelantimicrobialpeptide